DALLAS - 
(NewMediaWire) - October 21, 2024 - Sirona Biochem Corp: Stonegate Capital Partners initiates their coverage on Sirona Biochem Corp (TSX-V:SBM) (FSE: ZSB) (OTC: SRBCF).
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- GlycoProteMim™ is a potential standout in the premium skincare market
- Sirona is targeting profitability by 2025, with expected revenue from Allergan Aesthetic and the commercialization of GlycoProteMim™ set to drive growth.
- Sirona’s partnerships place it in a strong position to capture market share in the growing global skincare industry.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
